

Curriculum Vitae

Personal information Sine Buhl Naess-Schmidt

Work experience

1. Employer: Danish Medicines Agency, Regulatory and Clinical Assessments
 - Start date: 022022
 - End date:
 - Position: Senior Medical Officer
 - Activities: Clinical assessor of centralized, decentralized and national procedures. Since July 2023 Member of Biosimilar Medicinal Products Working Party (BWMP) (ongoing). June 2024-Dec. 2024 PDCO alternate. From Dec. 2024 COMP member (ongoing).
 - Country: Denmark
2. Employer: Danish Medicines Agency, Regulatory and Clinical Assessments
 - Start date: 052021
 - End date: 012022
 - Position: Medical Officer
 - Activities:
 - Country: Denmark
3. Employer: Bispebjerg University Hospital, Digestive Disease Center and Herlev University Hospital, Department of Gastroenterology
 - Start date: 062018
 - End date: 042021
 - Position: MD
 - Activities: Internal Medicine, Gastroenterology and Hepatology. Including work in the outpatient clinic and shifts in the emergency department.
 - Country: Denmark
4. Employer: Herlev University Hospital, Dept of Gastroenterology and Hepatology
 - Start date: 032012
 - End date: 042018
 - Position: Research position/ PhD-student
 - Activities: Clinical research with focus on inflammatory bowel disease, primarily treatment with Tumor Necrosis Factor-alpha blockers, therapeutic drug monitoring, and how to optimize treatment both in patients in remission and in patients with treatment failure. Further I have been coordinating investigator of a Nordic multicenter, double blinded, randomized, placebo controlled clinical trial examining if infliximab can safely be discontinued in patients with Crohn's disease in sustained complete remission on infliximab maintenance therapy.
 - Country: Denmark
5. Employer: Herlev University Hospital, Dept. of Clinical Oncology
 - Start date: 032010
 - End date: 022012
 - Position: MD
 - Activities: Including work in the outpatient clinic and shifts.
 - Country: Denmark
6. Employer: Amager Hospital, Dept of internal medicine
 - Start date: 052008
 - End date: 092009
 - Position: MD
 - Activities: Including work in the outpatient clinic and shifts in the emergency area.
 - Country: Denmark
7. Employer: Kiruna Hospital, Vårdcentral Graniten
 - Start date: 032008
 - End date: 052008
 - Position: MD
 - Activities: Including work in the clinic and shifts in the emergency area
 - Country: Sweden
8. Employer: General Practice, Copenhagen
 - Start date: 092007
 - End date: 032008
 - Position: Internship MD
 - Activities: Internship
 - Country: Denmark
9. Employer: Bispebjerg University Hospital Dept of Kardiology and Dept of Surgery
 - Start date: 092006
 - End date: 082007
 - Position: Internship MD
 - Activities: Internship
 - Country: Denmark

Education and training

1. Subject: Copenhagen University, Health and Medical Science
 - Start date: 072012
 - End date: 082018
 - Qualification: PhD: Clinical outcomes in anti_tumor necrosis factor alpha treated patients with inflammatory bowel disease _ Courses and clinical handling towards personalized therapy

- Organisation: Copenhagen University, Faculty of Health and Medical Sciences
 - Country: Denmark
2. Subject: Copenhagen University, Capital Regions
- Start date: 092006
 - End date: 032008
 - Qualification: Authorization to work independently as a MD
 - Organisation:
 - Country: Denmark
3. Subject: Copenhagen University
- Start date: 092000
 - End date: 062006
 - Qualification: MD
 - Organisation: Copenhagen University Faculty of Health and Medical Sciences
 - Country: Denmark

Additional information

Publications

Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis. Katibian DJ, Solitano V, Polk DB, Nguyen T, Ma C, Syal G, Kobayashi T, Hibi T, **Buhl S**, Ainsworth MA, Jairath V, Singh S. Clin Gastroenterol Hepatol. 2024 Jan;22(1):22-33.e6. doi: 10.1016/j.cgh.2023.08.039. Epub 2023 Sep 15. PMID: 37716619.

Identifying and understanding disease burden in patients with inflammatory bowel disease. Christensen KR, Ainsworth MA, Skougaard M, Steenholdt C, **Buhl S**, Brynskov J, Kristensen LE, Jørgensen TS. BMJ Open Gastroenterol. 2022 Oct;9(1):e000994. doi: 10.1136/bmjgast-2022-000994.

Discontinuation of Infliximab Therapy in Patients with Crohn's Disease. **S Buhl**, C Steenholdt, J Brynskov +20, for the Stop Infliximab Treatment (STOP-IT) Study Group. June 14, 2022. NEJM Evid 2022;1(8). Doi: 10.1056/EVIDoa2200061.
<https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200061>

Fatigue is a systemic extraintestinal disease manifestation largely independent of disease activity, chronicity, and nutritional deficiencies in inflammatory bowel disease on biologics. Christensen KR, Ainsworth MA, Steenholdt C, **Buhl S**, Skougaard M, Brynskov J, Jørgensen TS, Kristensen LE. Scand J Gastroenterol. 2022 Sep;57(9):1051-1057. doi: 10.1080/00365521.2022.2060049.

Drug Levels Associated With Optimal Discrimination Between Remission and Nonremission and Comparison of Antibody Assays During First Year of Stable Infliximab Maintenance Therapy in Inflammatory Bowel Disease. Dorn-Rasmussen M, **Buhl S**, Brynskov J, Bay JT, Bolstad N, Klausen TW, Warren DJ, Ainsworth MA, Steenholdt C. Ther Drug Monit. 2022 Apr 1;44(2):290-300. doi: 10.1097/FTD.0000000000000913.

A systematic monitoring approach to biologic therapies in inflammatory

bowel disease: patients' and physicians' preferences and adherence. Christensen KR, Steenholdt C, **Buhl S**, Brynskov J, Ainsworth MA. Scand J Gastroenterol. 2022 Mar;57(3):274-281. doi: 10.1080/00365521.2021.2002397.

Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. **Buhl S**, Dorn-Rasmussen M, Brynskov J, Ainsworth MA, Bendtzen K, Klausen PH, Bolstad N, Warren DJ, Steenholdt C. Scand J Gastroenterol. 2020 Aug;55(8):884-890. doi: 10.1080/00365521.2020.1786852.

Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study. **Buhl S**, Kristina Borghede M, Brynskov J, Steenholdt C, Rasmussen M, Andrew Ainsworth M. Scand J Gastroenterol. 2018 Aug;53(8):930-937. doi: 10.1080/00365521.2018.1481519.

Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease. **Buhl S**, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen OØ, Ainsworth MA. Inflamm Bowel Dis. 2017 Jul;23(7):1210-1217. doi: 10.1097/MIB.0000000000001117.

Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF- α Independent Crohn Disease. Steenholdt C, Coskun M, **Buhl S**, Bendtzen K, Ainsworth MA, Brynskov J, Nielsen OH. Medicine (Baltimore). 2016 Apr;95(16):e3417. doi: 10.1097/MD.00000000000003417.

Systematic Information to Health-Care Professionals about Vaccination Guidelines Improves Adherence in Patients With Inflammatory Bowel Disease in Anti-TNF α Therapy. Christensen KR, Steenholdt C, **Buhl SS**, Ainsworth MA, Thomsen OØ, Brynskov J. Am J Gastroenterol. 2015 Nov;110(11):1526-32. doi: 10.1038/ajg.2015.162.

High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumors. Hansen TV, Vikesaa J, **Buhl SS**, Rossing HH, Timmermans-Wielenga V, Nielsen FC. BMC Cancer. 2015 Feb 6;15:35. doi: 10.1186/s12885-015-1035-1.

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. **Buhl SS**, Steenholdt C, Brynskov J, Thomsen OØ, Bendtzen K, Ainsworth MA. BMJ Open. 2014 Dec 18;4(12):e005887. doi: 10.1136/bmjopen-2014-005887.

Projects

Coordinating investigator of a Nordic multicenter, double blinded, randomized, placebo controlled clinical trial examining if infliximab can safely be discontinued in patients with Crohn's disease in sustained complete remission on infliximab maintenance therapy (EudraCT no: 2012_002702_51). The study has been presented at Digestive Disease Week in May 2021, United European Gastroenterology Week (UEGW) in October 2021, Nordic IBD 2023 and main results are published.

Memberships

Other Relevant Information